{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"218.5","upperLimit":"396.4","value":"294.3"},{"groupId":"OG001","lowerLimit":"202.5","upperLimit":"284.9","value":"240.2"},{"groupId":"OG002","lowerLimit":"227.7","upperLimit":"351.4","value":"282.8"},{"groupId":"OG003","lowerLimit":"224.0","upperLimit":"357.6","value":"283.0"},{"groupId":"OG004","lowerLimit":"146.9","upperLimit":"1058","value":"394.1"},{"groupId":"OG006","lowerLimit":"182.7","upperLimit":"274.3","value":"223.8"},{"groupId":"OG007","lowerLimit":"193.9","upperLimit":"265.4","value":"226.9"},{"groupId":"OG008","lowerLimit":"174.6","upperLimit":"267.8","value":"216.2"},{"groupId":"OG009","lowerLimit":"251.5","upperLimit":"412.3","value":"322.0"}]}],"title":"Day 1 (n=6, 9, 23, 13, 3, 0, 22, 22, 14, 13)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"133.4","upperLimit":"266.9","value":"188.7"},{"groupId":"OG001","lowerLimit":"187.9","upperLimit":"364.8","value":"261.8"},{"groupId":"OG002","lowerLimit":"276.9","upperLimit":"567.3","value":"396.4"},{"groupId":"OG003","lowerLimit":"223.1","upperLimit":"409.7","value":"302.4"},{"comment":"Data could not be calculated because there were no subjects evaluated for this arm at the specified time point because of limited number of samples collected to characterize the terminal phase rate constant needed for the calculation of Vz/f.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"189.7","upperLimit":"270.1","value":"226.3"},{"groupId":"OG007","lowerLimit":"214.2","upperLimit":"293.9","value":"250.9"},{"groupId":"OG008","lowerLimit":"169.0","upperLimit":"314.6","value":"230.6"},{"groupId":"OG009","lowerLimit":"213.8","upperLimit":"350.7","value":"273.8"}]}],"title":"Day 15 (n=6, 9, 13, 9, 0, 0, 16, 16, 9, 12)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"24"},{"groupId":"OG008","value":"18"},{"groupId":"OG009","value":"15"}],"units":"Participants"}],"description":"Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Apparent volume of distribution during the terminal phase, calculated by CL/f/λz. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.Data was not available for 'Pimasertib (MSC1936369B) 60mg Twice Daily' arm as no subjects were considered evaluable because of limited number of samples collected to characterize the terminal phase rate constant needed for the calculation of Vz/f.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 15 milligram (mg) on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG000","title":"Pimasertib (MSC1936369B) 15mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 30 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG001","title":"Pimasertib (MSC1936369B) 30mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG002","title":"Pimasertib (MSC1936369B) 60mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 90 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG003","title":"Pimasertib (MSC1936369B) 90mg"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 45 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG004","title":"Pimasertib (MSC1936369B) 45mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG005","title":"Pimasertib (MSC1936369B) 60mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG006","title":"TNBC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG007","title":"NSCLC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG008","title":"CRC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG009","title":"MEL: Pimasertib 60mg Once Daily"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set. Here \"N\" signifies number of subjects evaluable for this outcome measure and \"n\" signifies the number of subjects evaluable at specific time points.","reportingStatus":"POSTED","timeFrame":"Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts","title":"Apparent Volume of Distribution of Total Pimasertib During the Terminal Phase Following Oral Administration (Vz/f) of Pimasertib","type":"SECONDARY","unitOfMeasure":"liter"}